Hemostasis in intracranial hemorrhage

Frontiers in Neurology

Volumn 8, Issue MAR, 2017, Pages

  Gulati, Deepak ^a   Dua, Dharti ^a   Torbey, Michel T ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Anticoagulants; Hemostasis; Intracerebral hemorrhage; New oral anticoagulants; Reversal of anticoagulation

Indexed keywords

ACTIVATED CARBON; ACTIVATED PROTHROMBIN COMPLEX; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; FRESH FROZEN PLASMA; IDARUCIZUMAB; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBIN INHIBITOR; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; BRAIN HEMATOMA; BRAIN HEMORRHAGE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; HEMOSTATIC TECHNIQUE; HUMAN; NONHUMAN; PRACTICE GUIDELINE; REVIEW; THROMBOCYTE TRANSFUSION;

EID: 85016146164     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2017.00080     Document Type: Review

References (85)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation (2013) 127(1):e6-245. doi:10.1161/CIR.0b013e318282ab8f
2. Broderick JP, Adams HP Jr, Barsan W, Feinberg W, Feldmann E, Grotta J, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a statement for healthcare professionals from a special writing group of the stroke council, American Heart Association. Stroke (1999) 30(4):905-15. doi:10.1161/01.STR.30.4.905
3. Zahuranec DB, Lisabeth LD, Sánchez BN, Smith MA, Brown DL, Garcia NM, et al. Intracerebral hemorrhage mortality is not changing despite declining incidence. Neurology (2014) 82(24):2180-6. doi:10.1212/WNL.0000000000000519
4. Li Q, Zhang G, Xiong X, Wang XC, Yang WS, Li KW, et al. Black hole sign: novel imaging marker that predicts hematoma growth in patients with intracerebral hemorrhage. Stroke (2016) 47(7):1777-81. doi:10.1161/STROKEAHA.116.013186
5. Brott T, Broderick J, Kothari R, Barsan W, Tomsick T, Sauerbeck L, et al. Early hemorrhage growth in patients with intracerebral hemorrhage. Stroke (1997) 28(1):1-5. doi:10.1161/01.STR.28.1.1
6. Fujii Y, Tanaka R, Takeuchi S, Koike T, Minakawa T, Sasaki O. Hematoma enlargement in spontaneous intracerebral hemorrhage. J Neurosurg (1994) 80(1):51-7. doi:10.3171/jns.1994.80.1.0051
7. Li Q, Huang YJ, Zhang G, Lv FJ, Wei X, Dong MX, et al. Intraventricular hemorrhage and early hematoma expansion in patients with intracerebral hemorrhage. Sci Rep (2015) 5:11357. doi:10.1038/srep11357
8. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, et al. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology (2006) 66(8):1175-81. doi:10.1212/01.wnl.0000208408.98482.99
9. Tuhrim S, Dambrosia JM, Price TR, Mohr JP, Wolf PA, Hier DB, et al. Intracerebral hemorrhage: external validation and extension of a model for prediction of 30-day survival. Ann Neurol (1991) 29(6):658-63. doi:10.1002/ana.410290614
10. Portenoy RK, Lipton RB, Berger AR, Lesser ML, Lantos G. Intracerebral haemorrhage: a model for the prediction of outcome. J Neurol Neurosurg Psychiatry (1987) 50(8):976-9. doi:10.1136/jnnp.50.8.976
11. Daverat P, Castel JP, Dartigues JF, Orgogozo JM. Death and functional outcome after spontaneous intracerebral hemorrhage. A prospective study of 166 cases using multivariate analysis. Stroke (1991) 22(1):1-6. doi:10.1161/01.STR.22.1.1
12. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage. A powerful and easy-to-use predictor of 30-day mortality. Stroke (1993) 24(7):987-93. doi:10.1161/01.STR.24.7.987
13. Mayer SA. Ultra-early hemostatic therapy for intracerebral hemorrhage. Stroke (2002) 34(1):224-9. doi:10.1161/01.STR.0000046458.67968.E4
14. Alberts MJ, Bertels C, Dawson DV. An analysis of time of presentation after stroke. JAMA (1990) 263(1):65-8. doi:10.1001/jama.1990.03440010063031
15. Lovelock CE, Molyneux AJ, Rothwell PM; Oxford Vascular Study. Change in incidence and aetiology of intracerebral haemorrhage in Oxfordshire, UK, between 1981 and 2006: a population-based study. Lancet Neurol (2007) 6(6):487-93. doi:10.1016/S1474-4422(07)70107-2
16. Naidech AM, Jovanovic B, Liebling S, Garg RK, Bassin SL, Bendok BR, et al. Reduced platelet activity is associated with early clot growth and worse 3-month outcome after intracerebral hemorrhage. Stroke (2009) 40(7):2398-401. doi:10.1161/STROKEAHA.109.550939
17. Thompson BB, Béjot Y, Caso V, Castillo J, Christensen H, Flaherty ML, et al. Prior antiplatelet therapy and outcome following intracerebral hemorrhage: a systematic review. Neurology (2010) 75(15):1333-42. doi:10.1212/WNL.0b013e3181f735e5
18. Creutzfeldt CJ, Weinstein JR, Longstreth WT Jr, Becker KJ, McPharlin TO, Tirschwell DL. Prior antiplatelet therapy, platelet infusion therapy, and outcome after intracerebral hemorrhage. J Stroke Cerebrovasc Dis (2009) 18(3):221-8. doi:10.1016/j.jstrokecerebrovasdis.2008.10.007
19. Ducruet AF, Hickman ZL, Zacharia BE, Grobelny BT, DeRosa PA, Landes E, et al. Impact of platelet transfusion on hematoma expansion in patients receiving antiplatelet agents before intracerebral hemorrhage. Neurol Res (2010) 32(7):706-10. doi:10.1179/174313209X459129
20. Naidech AM, Liebling SM, Rosenberg NF, Lindholm PF, Bernstein RA, Batjer HH, et al. Early platelet transfusion improves platelet activity and may improve outcomes after intracerebral hemorrhage. Neurocrit Care (2012) 16(1):82-7. doi:10.1007/s12028-011-9619-3
21. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, de Gans K, Koopman MM, Brand A, et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial. Lancet (2016) 387(10038):2605-13. doi:10.1016/S0140-6736(16)30392-0
22. Li X, Sun Z, Zhao W, Zhang J, Chen J, Li Y, et al. Effect of acetylsalicylic acid usage and platelet transfusion on postoperative hemorrhage and activities of daily living in patients with acute intracerebral hemorrhage. J Neurosurg (2013) 118(1):94-103. doi:10.3171/2012.9.JNS112286
23. Morrow JF, Braine HG, Kickler TS, Ness PM, Dick JD, Fuller AK. Septic reactions to platelet transfusions. A persistent problem. JAMA (1991) 266(4):555-8. doi:10.1001/jama.1991.03470040119033
24. Zeigler ZR, Megaludis A, Fraley DS. Desmopressin (d-DAVP) effects on platelet rheology and von Willebrand factor activities in uremia. Am J Hematol (1992) 39(2):90-5. doi:10.1002/ajh.2830390204
25. Gordz S, Mrowietz C, Pindur G, Park JW, Jung F. Effect of desmopressin (DDAVP) on platelet membrane glycoprotein expression in patients with von Willebrand's disease. Clin Hemorheol Microcirc (2005) 32(2):83-7.
26. Calmer S, Ferkau A, Larmann J, Johanning K, Czaja E, Hagl C, et al. Desmopressin (DDAVP) improves recruitment of activated platelets to collagen but simultaneously increases platelet endothelial interactions in vitro. Platelets (2014) 25(1):8-15. doi:10.3109/09537104.2013.767442
27. Mannucci PM, Remuzzi G, Pusineri F, Lombardi R, Valsecchi C, Mecca G, et al. Deamino-8-d-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med (1983) 308(1):8-12. doi:10.1056/NEJM198301063080102
28. Kim JH, Baek CH, Min JY, Kim JS, Kim SB, Kim H. Desmopressin improves platelet function in uremic patients taking antiplatelet agents who require emergent invasive procedures. Ann Hematol (2015) 94(9):1457-61. doi:10.1007/s00277-015-2384-1
29. Naidech AM, Maas MB, Levasseur-Franklin KE, Liotta EM, Guth JC, Berman M, et al. Desmopressin improves platelet activity in acute intracerebral hemorrhage. Stroke (2014) 45(8):2451-3. doi:10.1161/STROKEAHA.114.006061
30. Frontera JA, Lewin JJ III, Rabinstein AA, Aisiku IP, Alexandrov AW, Cook AM, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care (2016) 24(1):6-46. doi:10.1007/s12028-015-0222-x
31. Flaherty ML, Kissela B, Woo D, Kleindorfer D, Alwell K, Sekar P, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology (2007) 68(2):116-21. doi:10.1212/01.wnl.0000250340.05202.8b
32. Cucchiara B, Messe S, Sansing L, Kasner S, Lyden P; CHANT Investigators. Hematoma growth in oral anticoagulant related intracerebral hemorrhage. Stroke (2008) 39(11):2993-6. doi:10.1161/STROKEAHA.108.520668
33. Béjot Y, Cordonnier C, Durier J, Aboa-Eboulé C, Rouaud O, Giroud M. Intracerebral haemorrhage profiles are changing: results from the Dijon population-based study. Brain (2013) 136(Pt 2):658-64. doi:10.1093/brain/aws349
34. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med (2007) 120(8):700-5. doi:10.1016/j.amjmed.2006.07.034
35. Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M. Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke (2011) 42(9):2431-5. doi:10.1161/STROKEAHA.111.615260
36. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated after intracerebral hemorrhage? A decision analysis. Stroke (2003) 34(7):1710-6. doi:10.1161/01.STR.0000078311.18928.16
37. Neau JP, Couderq C, Ingrand P, Blanchon P, Gil R; VGP Study Group. Intracranial hemorrhage and oral anticoagulant treatment. Cerebrovasc Dis (2001) 11(3):195-200. doi:10.1159/000047638
38. Punthakee X, Doobay J, Anand SS. Oral-anticoagulant-related intracerebral hemorrhage. Thromb Res (2002) 108(1):31-6. doi:10.1016/S0049-3848(02)00398-5
39. Huttner HB, Schellinger PD, Hartmann M, Köhrmann M, Juettler E, Wikner J, et al. Hematoma growth and outcome in treated neurocritical care patients with intracerebral hemorrhage related to oral anticoagulant therapy: comparison of acute treatment strategies using vitamin K, fresh frozen plasma, and prothrombin complex concentrates. Stroke (2006) 37(6):1465-70. doi:10.1161/01.STR.0000221786.81354.d6
40. Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres M, Sobesky J, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA (2015) 313(8):824-36. doi:10.1001/jama.2015.0846
41. Hanger HC, Geddes JA, Wilkinson TJ, Lee M, Baker AE. Warfarin-related intracerebral haemorrhage: better outcomes when reversal includes prothrombin complex concentrates. Intern Med J (2013) 43(3):308-16. doi:10.1111/imj.12034
42. Broderick J, Connolly S, Feldmann E, Hanley D, Kase C, Krieger D, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association stroke council, high blood pressure research council, and the quality of care and outcomes in research interdisciplinary working group. Circulation (2007) 116(16):e391-413. doi:10.1161/CIRCULATIONAHA.107.183689
43. Watson HG, Baglin T, Laidlaw SL, Makris M, Preston FE. A comparison of the efficacy and rate of response to oral and intravenous Vitamin K in reversal of over-anticoagulation with warfarin. Br J Haematol (2001) 115(1):145-9. doi:10.1046/j.1365-2141.2001.03070.x
44. Whitling AM, Bussey HI, Lyons RM. Comparing different routes and doses of phytonadione for reversing excessive anticoagulation. Arch Intern Med (1998) 158(19):2136-40. doi:10.1001/archinte.158.19.2136
45. Nee R, Doppenschmidt D, Donovan DJ, Andrews TC. Intravenous versus subcutaneous vitamin K1 in reversing excessive oral anticoagulation. Am J Cardiol (1999) 83(2):286-8. doi:10.1016/S0002-9149(98)00842-X
46. Yasaka M, Sakata T, Minematsu K, Naritomi H. Correction of INR by prothrombin complex concentrate and vitamin K in patients with warfarin related hemorrhagic complication. Thromb Res (2002) 108(1):25-30. doi:10.1016/S0049-3848(02)00402-4
47. Butler AC, Tait RC. Management of oral anticoagulant-induced intracranial haemorrhage. Blood Rev (1998) 12(1):35-44. doi:10.1016/S0268-960X(98)90028-5
48. Choonara IA, Scott AK, Haynes BP, Cholerton S, Breckenridge AM, Park BK. Vitamin K1 metabolism in relation to pharmacodynamic response in anticoagulated patients. Br J Clin Pharmacol (1985) 20(6):643-8. doi:10.1111/j.1365-2125.1985.tb05123.x
49. Riegert-Johnson DL, Volcheck GW. The incidence of anaphylaxis following intravenous phytonadione (vitamin K1): a 5-year retrospective review. Ann Allergy Asthma Immunol (2002) 89(4):400-6. doi:10.1016/S1081-1206(10)62042-X
50. Fredriksson K, Norrving B, Stromblad LG. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke (1992) 23(7):972-7. doi:10.1161/01.STR.23.7.972
51. Ivascu FA, Howells GA, Junn FS, Bair HA, Bendick PJ, Janczyk RJ. Rapid warfarin reversal in anticoagulated patients with traumatic intracranial hemorrhage reduces hemorrhage progression and mortality. J Trauma (2005) 59(5):1131-7; discussion 1137-9. doi:10.1097/01.ta.0000189067.16368.83
52. Chapman SA, Irwin ED, Beal AL, Kulinski NM, Hutson KE, Thorson MA. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Ann Pharmacother (2011) 45(7-8):869-75. doi:10.1345/aph.1P605
53. Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke (2006) 37(1):151-5. doi:10.1161/01.STR.0000195047.21562.23
54. Lee SB, Manno EM, Layton KF, Wijdicks EF. Progression of warfarin-associated intracerebral hemorrhage after INR normalization with FFP. Neurology (2006) 67(7):1272-4. doi:10.1212/01.wnl.0000238104.75563.2f
55. Sarode R, Milling TJ Jr, Refaai MA, Mangione A, Schneider A, Durn BL, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation (2013) 128(11):1234-43. doi:10.1161/CIRCULATIONAHA.113.002283
56. Boulis NM, Bobek MP, Schmaier A, Hoff JT. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery (1999) 45(5):1113-8; discussion. doi:10.1097/00006123-199911000-00020
57. Leissinger CA, Blatt PM, Hoots WK, Ewenstein B. Role of prothrombin complex concentrates in reversing warfarin anticoagulation: a review of the literature. Am J Hematol (2008) 83(2):137-43. doi:10.1002/ajh.21046
58. Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H, et al. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost (2008) 6(4):622-31. doi:10.1111/j.1538-7836.2008.02904.x
59. Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. Thromb Res (2007) 121(1):9-16. doi:10.1016/j.thromres.2007.02.009
60. Parry-Jones AR, Di Napoli M, Goldstein JN, Schreuder FH, Tetri S, Tatlisumak T, et al. Reversal strategies for vitamin K antagonists in acute intracerebral hemorrhage. Ann Neurol (2015) 78(1):54-62. doi:10.1002/ana.24416
61. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke (2006) 37:256-62. doi:10.1161/01.STR.0000196989.09900.f8
62. Frontera JA, Gordon E, Zach V, Jovine M, Uchino K, Hussain MS, et al. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. Neurocrit Care (2014) 21(3):397-406. doi:10.1007/s12028-014-9972-0
63. Majeed A, Meijer K, Larrazabal R, Arnberg F, Luijckx GJ, Roberts RS, et al. Mortality in vitamin K antagonist-related intracerebral bleeding treated with plasma or 4-factor prothrombin complex concentrate. Thromb Haemost (2014) 111(2):233-9. doi:10.1160/TH13-07-0536
64. Steiner T, Poli S, Griebe M, Hüsing J, Hajda J, Freiberger A, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol (2016) 15(6):566-73. doi:10.1016/S1474-4422(16)00110-1
65. Freeman WD, Brott TG, Barrett KM, Castillo PR, Deen HG Jr, Czervionke LF, et al. Recombinant factor VIIa for rapid reversal of warfarin anticoagulation in acute intracranial hemorrhage. Mayo Clin Proc (2004) 79(12):1495-500. doi:10.4065/79.12.1495
66. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, et al. Efficacy and safety of recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med (2008) 358(20):2127-37. doi:10.1056/NEJMoa0707534
67. Mayer SA, Brun NC, Broderick J, Davis SM, Diringer MN, Skolnick BE, et al. Recombinant activated factor VII for acute intracerebral hemorrhage: US phase IIA trial. Neurocrit Care (2006) 4(3):206-14. doi:10.1385/NCC:4:3:206
68. Le Roux P, Pollack CV Jr, Milan M, Schaefer A. Race against the clock: overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage. J Neurosurg (2014) 121(Suppl):1-20. doi:10.3171/2014.8.paradigm
69. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol (2012) 110(3):453-60. doi:10.1016/j.amjcard.2012.03.049
70. Hart RG, Diener HC, Yang S, Connolly SJ, Wallentin L, Reilly PA, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke (2012) 43(6):1511-7. doi:10.1161/STROKEAHA.112.650614
71. Caldeira D, Rodrigues FB, Barra M, Santos AT, de Abreu D, Gonçalves N, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart (2015) 101(15):1204-11. doi:10.1136/heartjnl-2015-307489
72. Illanes S, Zhou W, Schwarting S, Heiland S, Veltkamp R. Comparative effectiveness of hemostatic therapy in experimental warfarin-associated intracerebral hemorrhage. Stroke (2011) 42(1):191-5. doi:10.1161/STROKEAHA.110.593541
73. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 103(6):1116-27. doi:10.1160/TH09-11-0758
74. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 124(14):1573-9. doi:10.1161/CIRCULATIONAHA.111.029017
75. Siegal DM, Cuker A. Reversal of novel oral anticoagulants in patients with major bleeding. J Thromb Thrombolysis (2013) 35(3):391-8. doi:10.1007/s11239-013-0885-0
76. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. N Engl J Med (2015) 373(6):511-20. doi:10.1056/NEJMoa1502000
77. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 365(10):883-91. doi:10.1056/NEJMoa1009638
78. Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J (2014) 35(28):1864-72. doi:10.1093/eurheartj/ehu046
79. Baumann Kreuziger LM, Keenan JC, Morton CT, Dries DJ. Management of the bleeding patient receiving new oral anticoagulants: a role for prothrombin complex concentrates. Biomed Res Int (2014) 2014:583794. doi:10.1155/2014/583794
80. Lazo-Langner A, Lang ES, Douketis J. Clinical review: clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. Crit Care (2013) 17(3):230. doi:10.1186/cc12592
81. Ansell JE. Universal, class-specific and drug-specific reversal agents for the new oral anticoagulants. J Thromb Thrombolysis (2016) 41(2):248-52. doi:10.1007/s11239-015-1288-1
82. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med (2015) 373(25):2413-24. doi:10.1056/NEJMoa1510991
83. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med (2016) 375(12):1131-41. doi:10.1056/NEJMoa1607887
84. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med (2014) 371(22):2141-2. doi:10.1056/NEJMc1411800
85. Kaatz S, Kouides PA, Garcia DA, Spyropolous AC, Crowther M, Douketis JD, et al. Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors. Am J Hematol (2012) 87(Suppl 1):S141-5. doi:10.1002/ajh.23202